Pharmacosmos Holding As v. Sandoz Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Pharmacosmos Holding A/S, Pharmacosmos A/S, and Pharmacosmos Therapeutics Inc. (Denmark & Delaware)
  • Defendant: Sandoz Inc. (Delaware)
  • Plaintiff's Counsel: Chiesa Shahinian & Giantomasi PC
• Case Identification: 2:26-cv-04948, D.N.J., 05/01/2026
• Venue Allegations: Venue is alleged to be proper based on Defendant Sandoz Inc.'s principal place of business in Princeton, New Jersey, and its systematic and continuous business activities within the district.
• Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) for a generic version of the iron-deficiency drug Injectafer constitutes an act of infringement and that the product's future sale will induce infringement of patents covering methods for mitigating the side effect of hypophosphatemia.
• Technical Context: The lawsuit concerns intravenous iron-carbohydrate complexes used to treat iron deficiency anemia, a market where managing treatment-related side effects is a key aspect of patient safety and clinical practice.
• Key Procedural History: The complaint notes that Defendant Sandoz previously settled litigation with the brand manufacturer of Injectafer (Vifor/American Regent), resulting in a license to launch its generic product on July 1, 2026. Plaintiff also states it previously filed suit against the Injectafer NDA holder (Daiichi Sankyo) over the same asserted patents, and that it provided Sandoz with a notice letter regarding the alleged infringement prior to filing this complaint.

Case Timeline

Date	Event
2018-10-29	Priority Date for '934 and '486 Patents
2019-07-10	Sandoz files ANDA No. 211725 (on or before this date)
2020-02-01	Injectafer label revised to add warnings for hypophosphatemia
2021-12-20	Vifor/American Regent announce settlement with Sandoz
2023-05-31	Injectafer label revised to add further warnings
2025-01-03	Injectafer label most recently revised
2025-05-13	U.S. Patent No. 12,295,934 Issues
2025-05-20	U.S. Patent No. 12,303,486 Issues
2025-09-22	Pharmacosmos files suit against Injectafer's NDA Holder
2026-03-11	Pharmacosmos sends Notice Letter to Sandoz
2026-04-02	Sandoz responds to Notice Letter
2026-05-01	Complaint Filed
2026-07-01	Sandoz's licensed generic launch date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,295,934 - "Treating Iron Deficiency with Ferric Carboxymaltose" (Issued May 13, 2025)

The Invention Explained

• Problem Addressed: The patent addresses the previously unrecognized clinical risks associated with repeated intravenous (IV) doses of ferric carboxymaltose (FCM) for treating iron deficiency Compl. ¶37 Prior to the invention, any resulting hypophosphatemia (low serum phosphate) was considered "transient, asymptomatic, and/or clinically irrelevant" '934 Patent, col. 2:39-41 The inventors discovered that a second dose of FCM causes an "auto-synergistic" two- to three-fold higher increase in intact fibroblast growth factor 23 (iFGF23), a hormone that regulates phosphate, leading to more severe hypophosphatemia and clinical consequences like "reduced muscle functions and increased bone turnover" '934 Patent, col. 3:19-26 '934 Patent, col. 9:46-51 Compl. ¶26
• The Patented Solution: The patent discloses a method to mitigate this newly discovered risk by proactively managing a patient's phosphate levels during a course of repeated FCM treatments Compl. ¶35 Specifically, the method requires measuring a patient's serum phosphate levels before administering a further dose of FCM and, if hypophosphatemia is detected, treating it before proceeding with the next dose '934 Patent, Claim 1 This protocol aims to prevent the compounding negative effects of repeat FCM dosing. The complaint references Figures 6 and 7 of the patent, which graphically depict the surprising auto-synergistic increase in iFGF23 levels after a subsequent dose of FCM Compl. ¶26
• Technical Importance: The invention provided the first method for safely administering repeat high-dose IV iron treatments by managing the newly identified risk of severe, iFGF23-mediated hypophosphatemia, which was previously unknown to the medical community Compl. ¶37

Key Claims at a Glance

• The complaint asserts independent claims 1 and 31 Compl. ¶54
• Independent Claim 1 Elements:
  • A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose;
  • administering a dose of ferric carboxymaltose;
  • determining that the subject needs a further dose;
  • prior to administering the further dose, measuring the subject's serum phosphate levels;
  • if the subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose; and
  • administering the further dose of ferric carboxymaltose.
• Independent Claim 31 Elements:
  • A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose;
  • administering a dose of ferric carboxymaltose;
  • determining that the subject needs a further dose;
  • prior to administering the further dose, first treating the subject with a medically indicated treatment for hypophosphatemia;
  • then measuring the subject's serum phosphate levels; and
  • administering the further dose of ferric carboxymaltose.
• The complaint reserves the right to assert claims 1-60 Compl. ¶51

U.S. Patent No. 12,303,486 - "Treating Iron Deficiency with Ferric Carboxymaltose" (Issued May 20, 2025)

The Invention Explained

• Problem Addressed: The patent addresses the previously unknown risk that FCM treatment frequently causes clinically significant, symptomatic hypophosphatemia, as opposed to the prior consensus that it was a transient and irrelevant side effect '486 Patent, col. 2:39-41 Compl. ¶41 The invention is based on the same discovery as the '934 patent: that repeated FCM doses auto-synergistically compound iFGF23 increases, exacerbating the condition '486 Patent, col. 3:19-26
• The Patented Solution: The patent claims a method for "reducing risk of symptomatic hypophosphatemia" through the same procedural safeguard as the '934 patent: testing a patient's serum phosphate levels and, if necessary, treating any existing hypophosphatemia before administering a subsequent dose of FCM '486 Patent, Claim 1 Compl. ¶40 The method is intended to prevent the development of symptomatic hypophosphatemia that could otherwise occur with repeated treatment '486 Patent, col. 15:1-17
• Technical Importance: This method provides a protocol to proactively manage a newly identified risk, allowing for the safer long-term use of FCM in patients who require multiple infusions to treat their iron deficiency Compl. ¶41

Key Claims at a Glance

• The complaint asserts independent claim 1 Compl. ¶89
• Independent Claim 1 Elements:
  • A method of reducing risk of symptomatic hypophosphatemia associated with repeated treatment of iron deficiency with ferric carboxymaltose;
  • administering a dose of ferric carboxymaltose;
  • determining that the subject needs a further dose;
  • prior to administering the further dose, measuring the subject's serum phosphate levels;
  • if the subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose; and
  • administering the further dose of ferric carboxymaltose.
• The complaint reserves the right to assert claims 1-29 Compl. ¶86

III. The Accused Instrumentality

Product Identification

• Sandoz's ANDA No. 211725 product, a generic version of Injectafer (ferric carboxymaltose injection) Compl. ¶1

Functionality and Market Context

• The infringement allegation is directed at the method of using Sandoz's product as will be instructed by its FDA-mandated labeling Compl. ¶18 The complaint alleges that Sandoz's label must be "materially the same" as the current label for the reference listed drug, Injectafer, specifically the January 2025 label Compl. ¶¶45-46 Compl. ¶49 This label allegedly instructs physicians to administer repeat courses of treatment for iron deficiency Compl. ¶59 Compl. ¶94 Crucially, the label is also alleged to contain warnings and instructions that direct healthcare professionals to monitor for, check, and treat hypophosphatemia in patients at risk, particularly those receiving a repeat course of treatment Compl. ¶57 Compl. ¶92 Plaintiff alleges that by providing a product with a label that instructs these specific monitoring and treatment steps, Sandoz will induce infringement of the asserted method claims Compl. ¶49 Sandoz is positioned to enter the market on or after July 1, 2026, under a license agreement resulting from prior litigation Compl. ¶21 Compl. ¶43

IV. Analysis of Infringement Allegations

'934 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of reducing severity of side effects associated with hypophosphatemia in connection with repeated treatment of iron deficiency with ferric carboxymaltose...	The accused label allegedly instructs a method of repeated treatment and includes warnings and directions that, if followed, reduce the severity of hypophosphatemia.	¶56; ¶57	col. 3:45-48
administering a dose of ferric carboxymaltose to said subject;	The accused label allegedly instructs physicians to administer doses of ferric carboxymaltose, the active ingredient in Sandoz's product.	¶58	col. 11:49-50
determining that said subject needs a further dose of ferric carboxymaltose;	The accused label allegedly instructs that treatment "may be repeated if IDA or iron deficiency in heart failure reoccurs," leading physicians to determine a need for a further dose.	¶59	col. 11:51-52
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels,	The accused label allegedly instructs physicians to "[c]heck serum phosphate levels prior to a repeat course of treatment" in at-risk patients.	¶60	col. 11:53-55
and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose;	The accused label allegedly instructs physicians to "[t]reat hypophosphatemia as medically indicated."	¶61	col. 11:55-58
and administering the further dose of ferric carboxymaltose to said subject.	The accused label allegedly instructs physicians on dosages for repeat courses of treatment.	¶62	col. 11:59-60

'486 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of reducing risk of symptomatic hypophosphatemia associated with repeated treatment of iron deficiency with ferric carboxymaltose...	The accused label allegedly instructs a method of repeated treatment and includes warnings and directions that, if followed, reduce the risk of symptomatic hypophosphatemia.	¶91; ¶92	col. 3:45-48
administering a dose of ferric carboxymaltose to said subject;	The accused label allegedly instructs physicians to administer doses of ferric carboxymaltose, the active ingredient in Sandoz's product.	¶93	col. 11:49-50
determining that said subject needs a further dose of ferric carboxymaltose;	The accused label allegedly instructs that treatment "may be repeated," leading physicians to determine a need for a further dose.	¶94	col. 11:51-52
prior to administering the further dose of ferric carboxymaltose, measuring said subject's serum phosphate levels,	The accused label allegedly instructs physicians to "[c]heck serum phosphate levels prior to a repeat course of treatment" in at-risk patients.	¶95	col. 11:53-55
and if said subject has hypophosphatemia, treating the hypophosphatemia as medically indicated prior to administering the further dose of ferric carboxymaltose;	The accused label allegedly instructs physicians to "[t]reat hypophosphatemia as medically indicated."	¶96	col. 11:55-58
and administering the further dose of ferric carboxymaltose to said subject.	The accused label allegedly instructs physicians on dosages for repeat courses of treatment.	¶97	col. 11:59-60

Identified Points of Contention

• Scope Questions: A potential dispute may arise from the preambles of the independent claims. The defense may argue that the actions instructed by the accused label do not necessarily result in "reducing severity of side effects" (as required by the '934 patent) or "reducing risk of symptomatic hypophosphatemia" (as required by the '486 patent), or that these are distinct outcomes and the label does not induce both.
• Technical Questions: A key technical question will be the sequence of steps induced by the label versus those required by the claims. The complaint asserts both Claim 1 ("measure, then treat") and Claim 31 ("treat, then measure") of the '934 patent. The infringement analysis may turn on whether the language of the accused label-which allegedly instructs physicians to "correct pre-existing hypophosphatemia" and also to "check serum phosphate levels"-can be shown to induce the specific, ordered sequence of steps recited in each of these distinct claims.

V. Key Claim Terms for Construction

• The Term: "treating the hypophosphatemia as medically indicated" '934 Patent, Claim 1 and "medically indicated treatment for hypophosphatemia" '934 Patent, Claim 31 '486 Patent, Claim 1
• Context and Importance: This term is central to the infringement allegation, as the plaintiff must show that the accused label instructs this affirmative treatment step. Practitioners may focus on this term because its definition will determine what kind of instruction on the label is sufficient to meet the claim limitation-for example, whether a general instruction to treat is enough, or if a specific type of treatment must be advised.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The claim language itself is broad ("as medically indicated"), suggesting any treatment deemed appropriate by a physician would suffice. The specification also states that the method comprises "treating the hypophosphatemia" without being limited to a specific agent '934 Patent, col. 12:35-43
  • Evidence for a Narrower Interpretation: The specification provides specific examples of treatments, such as "administration of vitamin D and/or phosphates" '934 Patent, col. 16:11-13 A defendant may argue that the term should be construed as limited to these or similar disclosed treatments, rather than any possible medical intervention.

VI. Other Allegations

• Indirect Infringement: The core of the complaint is inducement of infringement under 35 U.S.C. § 271(b). Plaintiff alleges that Sandoz, by marketing its ANDA product with a label that instructs healthcare providers to perform the patented methods, will actively and knowingly encourage infringement Compl. ¶49 Compl. ¶51 Compl. ¶77 Compl. ¶86 The complaint also alleges infringement under 35 U.S.C. § 271(e)(2) based on the submission of the ANDA itself for a use claimed in the patents Compl. ¶79 Compl. ¶104
• Willful Infringement: The complaint alleges Sandoz had knowledge of the asserted patents, creating a basis for willfulness. This knowledge is alleged to have arisen from at least two events: (1) Plaintiff's lawsuit filed on September 22, 2025, against the Injectafer NDA holder, which publicly alleged infringement of the same patents by the same label Sandoz is required to copy Compl. ¶76 Compl. ¶101; and (2) a direct notice letter sent by Plaintiff to Sandoz on March 11, 2026, which Sandoz acknowledged receiving (Compl. ¶¶47-48; Compl. ¶¶75, Compl. ¶100).

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of claim scope and interpretation: Can the instructions on Sandoz's product label be proven to induce infringement of two separate patents, one directed to "reducing severity of side effects" and the other to "reducing risk of symptomatic hypophosphatemia"? The court's interpretation of these preamble phrases will be critical.
• A second key question will be one of infringing sequence: Does the collection of instructions on the accused label-to "check" levels, "correct" pre-existing conditions, and "treat" as indicated-induce the specific, ordered steps of both the "measure, then treat" method of Claim 1 and the "treat, then measure" method of Claim 31 of the '934 patent?
• A third central issue will be willfulness: Given the complaint's specific allegations that Sandoz had knowledge of the asserted patents from both a prior public lawsuit and a direct notice letter well before its planned launch, the court will need to determine whether Sandoz's actions constitute willful infringement, which could expose it to enhanced damages if infringement is found.